Thanks nurapatch
Thus, the less inhibitory effects of MOR blockade in the SNc relative to VTA could account for relative increases in DA release in the dorsal striatum during NPW
Combination therapy For patients with type 2 diabetes mellitus to improve glycemic control in combination with sulfonylurea derivatives (triple combination: metformin + sitagliptin + sulfonylurea derivative) when diet and exercise regimen in combination with two of these three drugs (metformin, sitagliptin, or sulfonylurea derivatives) do not lead to adequate glycemic control
Keywords included terms related to glucagon-like peptide-1 receptor agonists (e.g., Glucagon-Like Peptide-1, GLP-1), mental health outcomes (e.g., Depression, Mental Disorder*, Psychiatric Disease*, Depressive Symptoms), and weight-related conditions (e.g., Obesity, Overweight, Weight Gain)